Solving manufacturing problems for L-carnitine-L-tartrate to improve the likelihood of successful product scale-up
Author:
Badawi Aliaa A.1, Hegazy Mahmoud M.2, Louis Dina13, Eldegwy Mohammed A.2
Affiliation:
1. Department of Pharmaceutics and Industrial Pharmacy Faculty of Pharmacy, Cairo University Cairo , Egypt 2. Research & Development Department, Mepaco-Medifood Company, El Sharkia , Egypt 3. Department of Pharmaceutics and Pharmaceutical Technology Faculty of Pharmacy and Drug Technology, Heliopolis University for Sustainable Development, Heliopolis , Egypt
Abstract
Abstract
L-carnitine-L-tartrate, a non-essential amino acid, is hygroscopic. This causes a problem in tablet production due to pronounced adhesion of tablets to punches. A 33 full factorial design was adopted to suggest a tablet formulation. Three adsorbents were suggested (Aerosil 200, Aerosil R972, talc) to reduce stickiness at three concentrations (1, 3 and 5 %), and three fillers (mannitol, Avicel PH 101, Dibasic calcium phosphate) were chosen to prepare 27 formulations. Micromeritic properties of formulations were studied, and tablets were prepared by wet granulation. Absence of picking, sticking or capping, recording of sufficient hardness, acceptable friability and tablet ejection force indicated formulation success. The resulting formulation prepared using Avicel PH 101 and 1 % Aerosil 200 was submitted to further investigation in order to choose the most suitable compression conditions using a 33 full factorial design. Variables included compression force, tableting rate and magnesium stearate (lubricant) concentration. The formulation prepared at compression force of 25 kN, using 2 % magnesium stearate, at a production rate of 30 tablets/ minute, was found to be the most appropriate scale up candidate.
Publisher
Walter de Gruyter GmbH
Subject
Pharmaceutical Science,Pharmacology,General Medicine
Reference23 articles.
1. 1. M. Nishimura, T. Tokoro, T. Takatani, N. Sato, M. Nishida, T. Hashimoto, S. Yamazaki, H. Kobayashi and T. Ono, Effects of intravenous l-carnitine on myocardial fatty acid imaging in hemodialysis patients: responders or non-responders to l-carnitine, Springerplus 4 (2015) 353-362; https://doi.org/10.1186/s40064-015-1119-z 2. 2. P. Mason, Dietary Supplements, 3rd ed., Pharmaceutical Press, London 2007. 3. 3. J. L. Flanagan, P. A. Simmons, J. Vehige, M. D. P. Wilcox and Q. Garett, Role of carnitine in disease, Nutr. Metab. (Lond) 7 (2010) 30; https://doi.org/10.1186/1743-7075-7-30 4. 4. A. Hassan, Y. Tsuda, A. Asai, K. Yokohma, K. Nakamura, T. Sujishi, H. Ohama, Y. Tsuchimoto, S. Fukunishi, U. M. Abdelaal, U. A. Arafa, A. T. Hassan, A. M. Kassem and K. Higuchi, Effects of oral L-Carnitine on liver functions after transarterial chemoembolization in intermediate-stage HCC patients, Mediators of Inflammation (2015), Article ID 608216, http://dx.doi.org/10.1155/2015/608216 5. 5. T. Răşanu, M. Mehedinţi-Hâncu, M. Alexianu, T. Mehedinţi, E. Gheorghe and L. Damian, Carnitine deficiency - case report, Roman. J. Morphol Embryol. 53 (2012) 203-206.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|